FMC Corporation and Tessenderlo Group Complete Minority Equity Investment

FMC Corporation received UK approval for Koban, a new herbicide with pethoxamid as the active ingredient, for use in oilseed rape. The company positions Koban as a residual partner product for weed control. This is FMC's third new herbicide active ingredient approved in the UK in recent years. Pethoxamid has existing regulatory history in Canada, the US, and the EU.

FMC Corporation submitted a regulatory filing for its herbicide rimisoxafen in Brazil, following a U.S. filing in July 2026. The herbicide targets resistant broadleaf weeds and is FMC's third novel herbicide submission in Brazil. FMC shares have fallen 72.6% in the past year, while the industry grew 10%.

FMC Corp. held its Q2 2026 earnings call. It reported Q1 revenue of $762 million, down 4% year over year, and adjusted EBITDA of $72 million. Full-year guidance calls for revenue of $3.6 billion to $3.8 billion and adjusted EBITDA of $670 million to $730 million. The company targets $1 billion debt reduction in 2026 via an India business sale and other disposals.

FMC Corporation reported Q2 2026 sales of $867.1M, down from $1,050.5M, and a net loss of $186.6M versus a $66.7M profit a year earlier. The company cut full-year 2026 revenue guidance to $3.50B to $3.70B. FMC kept its $0.08 quarterly dividend and cited cost and portfolio actions.

Shares of FMC Corporation (FMC +18.18%) rallied on Thursday, up 15.8% as of 12:03 p.m. EDT. The agricultural chemicals company reported earnings last night. While the initial market reaction was negative due to a revenue miss and guidance cut, there was apparently enough good news to trigger a relief rally in this very beaten-down stock. ( 18.18 %) $ 1.82 $ 11.83 $1.3BMarket cap calculated using publicly traded shares outstanding only.

FMC Corporation (NYSE: FMC) reported Q2 2026 revenue of $867 million, down 17% year over year, and Adjusted EBITDA of $153 million. GAAP net loss was $187 million, or $1.49 per diluted share. Cash from operations rose to $363 million. FMC lowered full-year 2026 guidance, including revenue excluding India to $3.50-$3.70 billion and Adjusted EBITDA to $620-$680 million.